In this webinar, experts will discuss the current state-of-the-art for iPSC generation and differentiation. The presentation will also highlight the development of advanced CGMP-compatible protocols for converting these cells into several cell types of therapeutic relevance.

Despite the potential benefits of induced pluripotent stem cells (iPSCs) to differentiate into multiple cell lineages and serve in regenerative medicine and immune cell therapy, CGMP-compatible implementation of the necessary methodologies remains challenging. At the technical level, the methodology to generate functional cell types from iPSCs must display a high degree of robustness, as well as scalability, to comply with the strict CGMP requirements.

In this webinar, experts will discuss the current state-of-the-art for iPSC generation and differentiation. The presentation will also highlight the development of advanced CGMP-compatible protocols for converting these cells into several cell types of therapeutic relevance, including retinal pigment epithelium (RPE), mesenchymal stem cells (MSCs), cardiomyocytes (CMs), and immune natural killer (NK) cells. There will also be discussion of the development of meaningful assays to assess purity and impurities in the product and to monitor potency.

Key Takeaways

Boris Greber, Ph.D, Head of Research & Development, iPSC, Catalent Cell & Gene Therapy.

Dr Greber is the Head of Research and Development (R&D), iPSC at Catalent Cell & Gene therapy in Europe. He joined Catalent as part of the RheinCell Therapeutics acquisition. He previously served as an independent research group leader at the Max Planck Institute for Molecular Biomedicine (Germany). Dr Greber is internationally recognized with a 15 year track record in basic and applied human iPSC research.

View original post here:
CGMP-compliant iPSC manufacturing and development of ... - Drug Target Review